DBV Technologies S.A.

Healthcare · Biotechnology · France

Last price 9.49 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 561.70M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ...